Hangzhou Biotest Biotech Co.,Ltd. (688767.SS)
CNY 38.92
(-0.97%)
CNY 38.92
(-0.97%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 146.45 Million CNY | -79.47% |
| 2022 | 926.41 Million CNY | -0.02% |
| 2021 | 980.61 Million CNY | 88.05% |
| 2020 | 520.91 Million CNY | 1189.02% |
| 2019 | 38.41 Million CNY | 18.39% |
| 2018 | 27.65 Million CNY | 170.88% |
| 2017 | 8.26 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 26.34 Million CNY | 61.37% |
| 2024 Q3 | 18.46 Million CNY | -59.31% |
| 2024 Q1 | 28.07 Million CNY | 36.54% |
| 2023 Q2 | 63.16 Million CNY | 270.54% |
| 2023 FY | - CNY | -79.47% |
| 2023 Q4 | 132.39 Million CNY | 450.57% |
| 2023 Q3 | -37.76 Million CNY | -159.79% |
| 2023 Q1 | 17.04 Million CNY | -82.02% |
| 2022 Q3 | 4.71 Million CNY | -98.43% |
| 2022 Q1 | 570.97 Million CNY | 306.65% |
| 2022 Q2 | 299.96 Million CNY | -47.46% |
| 2022 FY | - CNY | -0.02% |
| 2022 Q4 | 94.79 Million CNY | 1909.52% |
| 2021 FY | - CNY | 88.05% |
| 2021 Q4 | 140.41 Million CNY | -21.68% |
| 2021 Q3 | 179.26 Million CNY | 6.23% |
| 2021 Q2 | 168.75 Million CNY | -65.69% |
| 2021 Q1 | 491.83 Million CNY | 403.68% |
| 2020 FY | - CNY | 1189.02% |
| 2020 Q4 | 97.64 Million CNY | 47.94% |
| 2020 Q3 | 66 Million CNY | -76.28% |
| 2020 Q2 | 278.21 Million CNY | 253.93% |
| 2020 Q1 | 78.6 Million CNY | 0.0% |
| 2019 FY | - CNY | 18.39% |
| 2018 FY | - CNY | 170.88% |
| 2017 FY | - CNY | 0.0% |